I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Despite a significant decrease in mortality associated with cardiovascular disease in developed countries over the last decade,\[[@ref1][@ref2]\] acute myocardial infarction (AMI) continues to be a major cause of morbidity and mortality.\[[@ref3][@ref4]\] ST-segment elevation myocardial infarction (STEMI) constitutes more than 80% of MI patients in China;\[[@ref5]\] percutaneous coronary intervention (PCI) is the established acute reperfusion therapy for STEMI.\[[@ref6]\] STEMI remains the major contributor to death in females who suffer from cardiovascular disease at an older age compared with males,\[[@ref7][@ref8][@ref9]\] with females being reported to have more risk factors.\[[@ref10][@ref11]\] However, these studies have only examined hospital mortality and short-term outcomes. Furthermore, the age of onset of STEMI is ahead of time and tends to be younger.\[[@ref12]\] Therefore, there is little evidence on the effect of sex on prognosis following long-term STEMI in developing countries such as China. Research is required to understand whether sex-dependent differences influence the long-term prognosis of Chinese patients with STEMI undergoing PCI in adults. This study analyzed differences between the sexes for 30-day, 1-year, and 3-year net adverse clinical events (NACEs) in 1920 Chinese adult patients (≤60 years old) with STEMI undergoing PCI.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The study was conducted in accordance with the *Declaration of Helsinki* and was approved by the local ethics committee of the hospital. As a retrospective study and data analysis was performed anonymously, this study was exempt from the informed consent from patients.

Study population and study design {#sec2-2}
---------------------------------

This study retrospectively analyzed all consecutive patients admitted to the General Hospital of Shenyang Military Region with acute STEMI from January 01, 2006, to December 31, 2012, who underwent acute coronary angiography with the intention of PCI. Briefly, eligible patients aged 18--60 years had abnormal cardiac biomarkers, with at least one biomarker above the 99^th^ percentile of the upper reference limit within 24 h of admission. Patients must have presented directly to the enrolling PCI site within the first 24 h of presentation to ensure that primary clinical decision-making occurred at the enrolling site. We included patients with STEMI (*n* = 3179) that was confirmed by discharge diagnosis and electrocardiogram results. We excluded patients who were missing hospitalization data (*n* = 90), older than 60 years (*n* = 970), without PCI (*n* = 186), and lost to follow-up (*n* = 13), resulting in a final cohort of 1920 patients (1693 males and 227 females).

Data collection {#sec2-3}
---------------

Baseline characteristics, including demographic, treatment, and clinically relevant comorbidities, were collected by medical chart abstraction and standardized in-person interviews. Demographic characteristics included sex, age, smoking, previous medical history of diabetes, hyperlipidemia, hypertension, family history of coronary heart disease (CHD), diabetes, hypertension, and stroke. Information on prior myocardial infarction, PCI, peripheral artery disease, stroke, and chronic kidney disease was also obtained. Data regarding medication management included the use of aspirin, clopidogrel, β-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists, diuretics, statins, and nitrates. Echocardiography was ordered during hospitalization. All patients were initially administered with a loading dose of 300 mg aspirin and 600 mg clopidogrel before all procedures, followed by 75 mg clopidogrel per day for 3--12 months, along with 100 mg aspirin daily indefinitely, and treated with PCI by two experienced interventional cardiologists. All definitions were in accordance with the American College of Cardiology. Data were extracted by review of records from the emergency room, catheterization laboratory, and intensive care. All patients gave their intervention informed consent.

Follow-up and endpoints {#sec2-4}
-----------------------

All the 1920 STEMI patients were followed by telephone or hospital visits at 30 days, 6 months, 12 months, and 3 years after the index procedure and every year thereafter. Outcome of patients was retrieved from the interhospital computer system or by telephone interview. The primary observational outcome for the study was the occurrence of long-term NACEs, defined as the composite of any bleeding or major adverse cardiac or cerebral events (MACCEs), including all-cause death, reinfarction, and clinically indicated target vessel revascularization (TVR) or stroke. Long-term NACE was defined as 3 years during the observation period. Secondary observational outcomes included all separate components of the primary outcome, at 30-day, 1-year, and 3-year MACCE as well as bleeding and 30-day and 1-year NACE.

Definitions {#sec2-5}
-----------

STEMI was diagnosed if there was evidence of persistent chest pain for longer than 30 min and electrocardiogram changes with ST elevation \>2 mm in at least two precordial leads or \>1 mm in the limb leads or a new left bundle branch block. Successful primary PCI was \<30% residual stenosis of culprit lesions and three coronary flows, assessed visually. Multivessel disease was at least one additional ≥70% stenosis in a major coronary vessel besides the culprit lesion. Cardiac death included any death due to an evident cardiac cause, any death related to PCI, or death from an unknown reason. Revascularization of the target vessel was defined as stenosis of any target vessel above 50% of the diameter of the vessel based on quantitative coronary angiography in the presence of objective evidence of ischemia from noninvasive or invasive testing or symptoms. The diagnosis of reinfarction was based on the evidence of new or presumably new ST-segment elevation in two consecutive leads and an increase in biochemical markers of myocardial necrosis.\[[@ref13]\] Stroke was defined as the rapid onset of a new, persistent, neurologic deficit lasting at least 24 h (or resulting in death before 24 h). To compare with other trials using Academic Research Consortium (ARC) MI definitions, we also adjudicated MI data according to ARC definitions.\[[@ref14]\]

Statistical analysis {#sec2-6}
--------------------

Continuous and categorical variables are presented as mean ± standard deviation (SD) and percentages. All data were compared using parametric Student\'s *t*-tests, Chi-square or Fisher\'s exact tests, and Wilcoxon tests, as appropriate. Propensity score matching between males and females was performed as a 1:1 propensity score-matching analysis using the nearest-neighbor matching within a caliper of 0.1 SD of pooled propensity scores. Cumulative incidence rates of unadjusted NACE were evaluated using the Kaplan--Meier method, and log-rank tests were used to calculate differences between females and males. Cox regression model analysis was used to identify factors associated with adjusted 3-year NACE. Multivariate analysis for 3-year NACE was performed using Cox proportional hazards regression modeling. The results are presented as adjusted hazard ratios (*HR*s) with a 95% confidence interval (*CI*). All analyses were performed using SPSS 22.0 software for Windows (IBM Corp., Armonk, NY, USA). *P* values were two sided and *P* \< 0.05 was considered statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Study population and baseline characteristics {#sec2-7}
---------------------------------------------

Of 1920 patients, 227 (11.82%) were female and 1693 (88.18%) were male. Their baseline characteristics are presented in [Table 1.1](#T1){ref-type="table"}. Compared with males, females were slightly older (mean age 57.47 ± 6.14 years *vs*. 51.87 ± 8.30 years, *t* = −12.317, *P* \< 0.001) and were more likely to have diabetes mellitus (25.55% in females *vs*. 17.25% in males, *χ*^2^ = 9.258, *P* = 0.002), hypertension (56.83% *vs*. 45.48%, *χ*^2^ = 10.350, *P* = 0.001), and chronic kidney disease (2.20% *vs*. 0.65%, *χ*^2^ = 4.113, *P* = 0.043). More males had a history of smoking (76.90% in males *vs*. 28.19% in females, *χ*^2^ = 231.355, *P* \< 0.001) and were less likely to have hyperlipidemia (30.01% vs. 30.84%, *χ*^2^ = 0.066, *P* = 0.798). After propensity matching, the demographics and clinical parameters were well balanced between the groups; there were 290 propensity-matched patients \[145 females and 145 males, [Table 1.2](#T2){ref-type="table"}\].

###### 

Baseline characteristics of STEMI patients treated with PCI according to gender

  Characteristics                   Males (*n* = 1693)   Females (*n* = 227)   Statistics   *P*
  --------------------------------- -------------------- --------------------- ------------ ---------
  Demographics                                                                              
   Age (years)                      51.87 ± 8.30         57.47 ± 6.14          −12.317\*    \<0.001
  Measurements                                                                              
   SBP (mmHg)                       126.11 ± 37.70       126.22 ± 20.32        −0.041\*     0.967
   DBP (mmHg)                       77.27 ± 14.44        76.67 ± 13.73         0.596\*      0.551
   Heart rate (beats/min)           76.80 ± 14.89        77.97 ± 15.14         −1.114\*     0.266
  Medical history                                                                           
   Hypertension                     770 (45.48)          129 (56.83)           10.350^†^    0.001
   Diabetes mellitus                292 (17.25)          58 (25.55)            9.258^†^     0.002
   Hyperlipidemia                   508 (30.01)          70 (30.84)            0.066^†^     0.798
   Peripheral artery disease        17 (1.00)            3 (1.32)              0.009^†^     0.925
   Stroke                           164 (9.69)           24 (10.57)            0.178^†^     0.673
   Chronic kidney disease           11 (0.65)            5 (2.20)              4.113^†^     0.043
   Smoking                          1302 (76.90)         64 (28.19)            231.355^†^   \<0.001
  Prior history                                                                             
   Prior MI                         153 (9.04)           18 (7.93)             0.303^†^     0.582
   Prior PCI                        121 (7.15)           10 (4.41)             2.367^†^     0.124
  Family history                                                                            
   Family history of CHD            171 (10.10)          21 (9.25)             0.160^†^     0.464
   Family history of hypertension   157 (9.27)           19 (8.37)             0.196^†^     0.658
   Family history of DM             53 (3.13)            8 (3.52)              0.101^†^     0.751
   Family history of stroke         53 (3.13)            12 (5.29)             2.844^†^     0.092
  Medication                                                                                
   Aspirin                          1691 (99.88)         227 (100.00)          0.000^†^     1.000
   Clopidogrel                      1690 (99.82)         226 (99.56)           0.002^†^     0.967
   ACEI/ARBs                        1223 (72.24)         161 (70.93)           0.172^†^     0.679
   Beta-blocker                     1404 (82.93)         185 (81.50)           0.288^†^     0.592
   Nitrates                         1422 (83.99)         193 (85.02)           0.159^†^     0.690
   Statin                           1298 (76.67)         167 (73.57)           1.064^†^     0.302
   Diuretic                         901 (53.22)          136 (59.91)           3.610^†^     0.057
  Laboratory                                                                                
   Hemoglobin (g/L)                 144.57 ± 15.83       125.73 ± 14.51        16.894\*     \<0.001
   Triglyceride (mmol/L)            1.63 (1.21, 2.36)    1.80 (1.21, 2.49)                  0.110
   LDL (mmol/L)                     2.53 (2.12, 3.00)    2.72 (2.27, 3.29)                  \<0.001
   HDL (mmol/L)                     1.36 (1.11, 1.63)    1.43 (1.23, 1.71)                  0.003
   Total cholesterol (mmol/L)       4.70 ± 1.15          4.98 ± 1.10           −3.508\*     \<0.001
   eGFR (ml/min)                    87.55 ± 18.03        103.12 ± 22.22        −11.834\*    \<0.001
  Killip class                                                                              
   1                                1391 (82.16)         169 (74.45)           8.578^†^     0.035
   2                                218 (12.88)          39 (17.18)                         
   3                                39 (2.30)            9 (3.96)                           
   4                                45 (2.66)            10 (4.41)                          
  Symptom onset time (h)            4.50 (3.00, 7.00)    7.00 (4.00, 10.00)                 \<0.001
  Angiographic characteristics                                                              
   Diseased vessels                                                                         
    Single vessel disease           543 (32.07)          45 (19.82)            18.284^†^    \<0.001
    Double vessel disease           587 (34.67)          79 (34.80)                         
    Three vessel disease            563 (33.25)          103 (45.37)                        
   Number of stents                 1.00 (1.00, 2.00)    1.00 (1.00, 2.00)                  0.189
   Average stent diameter (mm)      3.16 ± 1.17          3.01 ± 0.38           1.942\*      0.052
   Average stent length (mm)        26.56 ± 5.91         26.03 ± 5.33          1.274\*      0.203

Data are presented as mean ± SD, *n* (%) or median (25^th^, 75^th^). \**t* values; ^†^*χ*^2^ values. SD: Standard deviation; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; CHD: Coronary heart disease; DM: Diabetes mellitus; ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin II receptor blockers; LDL: Low-density lipoprotein-cholesterol; HDL: High-density lipoprotein-cholesterol; eGFR: Estimated glomerular filtration rate; STEMI: ST-elevation myocardial infarction.

###### 

Baseline characteristics of STEMI patients treated with PCI according to gender by propensity score matching

  Characteristics                   Males (*n* = 145)   Females (*n* = 145)   Statistics   *P*
  --------------------------------- ------------------- --------------------- ------------ ---------
  Demographics                                                                             
   Age (years)                      54.97 ± 7.54        56.40 ± 6.65          −1.717\*     0.087
  Measurements                                                                             
   SBP (mmHg)                       127.32 ± 21.48      125.50 ± 20.76        0.734\*      0.464
   DBP (mmHg)                       76.27 ± 14.13       77.02 ± 14.16         −0.453\*     0.651
   Heart rate (beats/min)           77.00 ± 15.38       77.57 ± 15.20         −0.319\*     0.750
  Medical history                                                                          
   Hypertension                     74 (51.03)          78 (53.79)            0.221^†^     0.638
   Diabetes mellitus                28 (19.31)          35 (24.14)            0.994^†^     0.319
   Hyperlipidemia                   40 (27.59)          46 (31.72)            0.595^†^     0.442
   Peripheral artery disease        2 (1.38)            0                     0.503^†^     0.478
   Stroke                           19 (13.10)          13 (8.97)             1.265^†^     0.261
   Chronic kidney disease           2 (1.38)            3 (2.07)              0.000^†^     1.000
   Smoking                          62 (42.76)          57 (39.31)            0.356^†^     0.551
  Prior history                                                                            
   Prior MI                         9 (6.21)            11 (7.59)             0.215^†^     0.643
   Prior PCI                        8 (5.52)            6 (4.14)              0.300^†^     0.584
  Family history                                                                           
   Family history of CHD            13 (8.97)           13 (8.97)             0.000^†^     1.000
   Family history of hypertension   14 (9.66)           12 (8.28)             0.169^†^     0.681
   Family history of DM             4 (2.76)            4 (2.76)              0.000^†^     1.000
   Family history of stroke         9 (6.21)            6 (4.14)              0.633^†^     0.426
  Medication                                                                               
   Aspirin                          145 (100.00)        145 (100.00)          0.000^†^     1.000
   Clopidogrel                      145 (100.00)        144 (99.31)           0.000^†^     1.000
   ACEI/ARBs                        89 (61.38)          104 (71.72)           3.485^†^     0.062
   Beta-blocker                     122 (84.14)         115 (79.31)           1.131^†^     0.288
   Nitrates                         130 (89.66)         124 (85.52)           1.142^†^     0.285
   Statin                           100 (68.97)         105 (72.41)           0.416^†^     0.519
   Diuretic                         84 (57.93)          81 (55.86)            0.127^†^     0.722
  Laboratory                                                                               
   Hemoglobin (g/L)                 130.48 ± 14.84      129.20 ± 14.52        0.744\*      0.457
   Triglyceride (mmol/L)            1.40 (1.04, 2.07)   1.80 (1.21, 2.49)                  0.069
   LDL (mmol/L)                     2.58 (2.18, 3.18)   2.72 (2.27, 3.29)                  0.138
   HDL (mmol/L)                     1.41 (1.15, 1.66)   1.43 (1.23, 1.71)                  0.367
   Total cholesterol (mmol/L)       4.78 ± 1.26         4.86 ± 1.05           −0.610\*     0.542
   eGFR (ml/min)                    92.69 ± 22.36       96.72 ± 20.64         −1.595\*     0.112
  Killip class                                                                             
   1                                111 (76.55)         109 (75.17)           0.110^†^     0.979
   2                                19 (13.10)          20 (13.79)                         
   3                                7 (4.83)            8 (5.52)                           
   4                                8 (5.52)            8 (5.52)                           
  Symptom onset time (h)            4.00 (2.00, 5.50)   7.00 (4.25, 11.00)                 \<0.001
  Angiographic characteristics                                                             
   Diseased vessels                                                                        
    Single vessel disease           29 (20.00)          33 (22.76)            0.918^†^     0.632
    Double vessel disease           48 (33.10)          52 (35.86)                         
    Three vessel disease            68 (46.90)          60 (41.38)                         
   Number of stents                 1.00 (1.00, 2.00)   1.00 (1.00, 2.00)                  0.391
   Average stent diameter (mm)      3.26 ± 0.47         3.18 ± 0.45           1.405\*      0.161
   Average stent length (mm)        26.30 ± 5.49        26.25 ± 5.29          0.076\*      0.939

Data are presented as mean ± SD, *n* (%) or median (25^th^, 75^th^). \**t* values; ^†^*χ*^2^ values. SD: Standard deviation; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; CHD: Coronary heart disease; DM: Diabetes mellitus; ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin II receptor blockers; LDL: Low-density lipoprotein-cholesterol; HDL: High-density lipoprotein-cholesterol; eGFR: Estimated glomerular filtration rate; STEMI: ST-elevation myocardial infarction.

For biochemistry, compared with males, females had higher average low-density lipoprotein cholesterol (2.72 \[2.27, 3.29\] vs. 2.53 \[2.12, 3.00\], *P* \< 0.001), high-density lipoprotein (1.43 \[1.23, 1.71\] vs. 1.36 \[1.11, 1.63\], *P* = 0.003), total cholesterol (4.98 ± 1.10 vs. 4.70 ± 1.15, *t* = −3.508, *P* \< 0.001), and estimated glomerular filtration rate (103.12 ± 22.22 vs. 87.55 ± 18.03, *t* = −11.834, *P* \< 0.001) whereas hemoglobin (144.57 ± 15.83 vs. 125.73 ± 14.51, *t* = 16.894, *P* \< 0.001) in males was significantly higher than females. There were no differences in pharmacologic management during hospitalization between sexes. Females had a higher Killip class (≥3) than males (8.37% vs. 4.96%, *χ*^2^ = 8.578, *P* = 0.035). Females had significantly longer time from symptom onset to treatment (4.50 \[3.00, 7.00\] h vs. 7 h \[4.00, 10.00\], *P* \< 0.001). In angiographic characteristics and procedural results, females had a worse risk profile than males, with more multivessel diseases (80.17% vs. 67.92%, *χ*^2^ = 18.284, *P* \< 0.001). Males had a relatively larger reference vessel diameter (\[3.16 ± 1.17\] mm vs. \[3.01 ± 0.38\] mm, *t* = 1.942, *P* = 0.052). In propensity score-adjusted data, females had also significantly longer time from symptom onset to treatment (4 \[2.00, 5.00\] h vs. 7 \[4.25, 11.00\] h, *P* \< 0.001), and other clinical characteristics were no significant differences between females and males \[[Table 1.2](#T2){ref-type="table"}\].

Survival analysis of clinical outcomes {#sec2-8}
--------------------------------------

The results of 30-day, 1-year, and 3-year clinical outcomes for both groups are shown in [Table 2.1](#T3){ref-type="table"}. The incidence of 30-day NACE occurred in 12 (5.28%) female patients and 35 (2.07%) male patients (log rank *P* = 0.002). The rates of MACCE and myocardial infarction for females were significantly higher than males (females vs. males 4.84% vs. 1.59%, log rank *P* = 0.001; 1.32% vs. 0.12%, log rank *P* = 0.001). After propensity-matched adjustment, 30-day NACE was similar in both groups \[[Table 2.2](#T4){ref-type="table"}\].

###### 

Unadjusted outcomes of STEMI patients treated with PCI according to gender

  Characteristics                      Males (*n* = 1693)   Females (*n* = 227)   Statistics   *P*^\*^
  ------------------------------------ -------------------- --------------------- ------------ ---------
  30-day outcomes                                                                              
   NACE                                35 (2.07)            12 (5.28)             9.142        0.002
    MACCE                              27 (1.59)            11 (4.84)             11.476       0.001
     All-cause death                   14 (0.83)            5 (2.20)              3.791        0.052
      Cardiac death                    14 (0.83)            4 (1.76)              1.858        0.173
     All MI                            2 (0.12)             3 (1.32)              11.160       0.001
     Stroke                            1 (0.06)             1 (0.44)              2.798        0.094
     Target vessel revascularization   10 (0.59)            2 (0.88)              0.427        0.513
    Bleeding                           8 (0.47)             1 (0.44)              0.005        0.943
  1-year outcomes                                                                              
   NACE                                120 (7.09)           29 (12.78)            9.456        0.002
    MACCE                              100 (5.91)           27 (11.89)            11.794       0.001
     All-cause death                   35 (2.07)            9 (3.96)              3.250        0.071
      Cardiac death                    31 (1.83)            7 (3.08)              1.657        0.198
     All MI                            18 (1.06)            4 (1.76)              0.881        0.348
     Stroke                            5 (0.30)             3 (1.32)              5.104        0.024
     Target vessel revascularization   42 (2.48)            11 (4.84)             4.747        0.029
    Bleeding                           20 (1.18)            2 (0.88)              0.161        0.689
  3-year outcomes                                                                              
   NACE                                193 (11.40)          49 (21.59)            19.258       \<0.001
    MACCE                              168 (9.92)           43 (18.94)            16.960       \<0.001
     All-cause death                   58 (3.43)            11 (4.85)             1.035        0.253
      Cardiac death                    44 (2.60)            10 (4.41)             2.608        0.106
     All MI                            31 (1.83)            8 (3.52)              2.899        0.089
     Stroke                            7 (0.41)             4 (1.76)              6.433        0.011
     Target vessel revascularization   73 (4.31)            19 (8.37)             5.896        0.015
    Bleeding                           24 (1.42)            7 (3.08)              3.453        0.063

Data are presented as *n* (%). \*Log-rank tests. STEMI: ST-elevation myocardial infaction; PCI: Percutaneous coronary intervention; MACCE: Major adverse cardiac and cerebrovascular event; NACE: Net adverse clinical event; MI: Myocardial infarction.

###### 

Adjusted outcomes of STEMI patients treated with PCI according to gender by propensity score matching

  Characteristics                      Males (*n* = 145)   Females (*n* = 145)   Statistics   *P*^\*^
  ------------------------------------ ------------------- --------------------- ------------ ---------
  30-day outcomes                                                                             
   NACE                                7 (4.83)            10 (6.90)             0.519        0.471
    MACCE                              5 (3.45)            9 (6.21)              1.105        0.293
     All-cause death                   1 (0.69)            5 (3.45)              2.670        0.102
      Cardiac death                    1 (0.69)            4 (2.76)              1.808        0.179
     All MI                            0                   3 (2.07)              3.021        0.082
     Stroke                            0                   1 (0.69)              1.000        0.317
     Target vessel revascularization   4 (2.76)            0                     4.042        0.044
    Bleeding                           2 (1.38)            1 (0.69)              0.355        0.551
  1-year outcomes                                                                             
   NACE                                16 (11.03)          24 (16.55)            1.937        0.164
    MACCE                              12 (8.28)           22 (15.17)            3.228        0.072
     All-cause death                   2 (1.38)            8 (5.52)              3.705        0.054
      Cardiac death                    2 (1.38)            6 (4.14)              2.015        0.156
     All MI                            1 (0.69)            4 (2.76)              1.834        0.176
     Stroke                            0                   3 (2.07)              3.021        0.082
     Target vessel revascularization   4 (2.76)            7 (4.83)              0.277        0.599
    Bleeding                           4 (2.76)            2 (1.38)              0.688        0.407
  3-year outcomes                                                                             
   NACE                                20 (13.79)          38 (26.21)            7.058        0.008
    MACCE                              15 (10.34)          33 (22.76)            7.802        0.005
     All-cause death                   4 (2.76)            10 (6.90)             2.709        0.100
      Cardiac death                    3 (2.07)            8 (5.52)              2.354        0.125
     All MI                            2 (1.38)            7 (4.83)              2.857        0.091
     Stroke                            0                   3 (2.07)              3.021        0.082
     Target vessel revascularization   9 (6.21)            13 (8.97)             0.079        0.400
    Bleeding                           5 (3.45)            5 (3.45)              0.000        0.988

Data are presented as *n* (%). \*Log-rank tests. STEMI: ST-elevation myocardial infarction; PCI: Percutaneous coronary intervention; MACCE: Major adverse cardiac and cerebrovascular event; NACE: Net adverse clinical event; MI: Myocardial infarction.

At the 1-year follow-up, females continued to show increases in NACE compared with males (12.78% vs. 7.09%, log rank *P* = 0.002). In addition, females had a higher incidence of MACCE (11.89% vs. 5.91%, log rank *P* = 0.001), stroke (1.32%vs. 0.30%, log rank *P* = 0.024), and TVR (4.84% vs. 2.48%, log rank *P* = 0.029) compared with males. In the propensity-matched analysis, sex was no longer associated with a higher 1-year NACE \[16.55% vs. 11.03%, log rank *P* = 0.164, [Table 2.2](#T4){ref-type="table"}\].

Females had a significantly higher unadjusted 3-year NACE (21.59% vs. 11.40%, log rank *P* \< 0.001) and a higher incidence of MACCE (18.94% vs. 9.92%, log rank *P* \< 0.001), stroke (1.76% vs. 0.41%, log rank *P* = 0.011), and TVR (8.37% vs. 4.31%, log rank *P* = 0.015) compared with males. There were no differences in all-cause death (females vs. males) (4.85 vs. 3.43%, log rank *P* = 0.253), myocardial infarction (3.52% vs. 1.83%, log rank *P* = 0.089), and bleeding \[3.08% vs. 1.42%, log rank *P* = 0.063, [Table 2.1](#T3){ref-type="table"}\]. In the propensity-matched analysis, the 3-year incidence of NACE (26.21% vs. 13.79%, log rank *P* = 0.008) and MACCE (22.76% vs. 10.34%, log rank *P* = 0.005) were significantly higher in females than males. There were no significant differences between groups for all-cause death (females vs. males) (6.90% vs. 2.76%, log rank *P* = 0.100), cardiac death (5.52% vs. 2.07%, log rank *P* = 0.125), myocardial infarction (4.83% vs. 1.38%, log rank *P* = 0.091), stroke (2.07% vs. 0, log rank *P* = 0.082), TVR (8.97% vs. 6.21%, log rank *P* = 0.400), and bleeding \[3.45% vs. 3.45%, log rank *P* = 1.000; [Figure 1](#F1){ref-type="fig"} and [Table 2.2](#T4){ref-type="table"}\].

![Survival salvage curves of the study. (a) Unadjusted 3-year cumulative incidence of NACE; (b) unadjusted 3-year cumulative incidence of MACCE; (c) adjusted 3-year cumulative incidence of NACE by propensity score matching; (d) adjusted 3-year cumulative incidence of MACCE by propensity score matching. Red line represents females group; black line represents males group. NACE: Net adverse clinical event; MACCE: Major adverse cardiac and cerebrovascular event.](CMJ-131-1420-g001){#F1}

Multivariate analysis {#sec2-9}
---------------------

Cox regression analysis with propensity matching showed that female (*HR*: 2.557, 95% *CI*: 1.415--4.620, *P* = 0.002), hypertension (*HR*: 2.017, 95% *CI*: 1.138--3.576, *P* = 0.016), and family history of CHD (*HR*: 2.256, 95% *CI*: 1.115--4.566, *P* = 0.024) were independent risk factors for NACE. The number of stents (*HR*: 0.625, 95% *CI*: 0.437--0.894, *P* = 0.010) was independent protective factors of NACE \[[Table 3](#T5){ref-type="table"}\].

###### 

Independent predictors of 3-year NACE by propensity score matching

  Characteristics                  *HR*    95% *CI*       *P*
  -------------------------------- ------- -------------- -------
  Female                           2.557   1.415--4.620   0.002
  Symptom onset time               0.948   0.890--1.009   0.093
  Killip class                     1.160   0.851--1.582   0.347
  Hypertension                     2.017   1.138--3.576   0.016
  Chronic kidney disease           2.716   0.495--9.570   0.303
  Cholesterol                      0.845   0.659--1.083   0.183
  Diseased vessels                 1.153   0.809--1.642   0.431
  Family history of CHD            2.256   1.115--4.566   0.024
  Family history of hypertension   1.855   0.882--3.901   0.103
  The number of stents             0.625   0.437--0.894   0.010
  Average stent diameter           0.513   0.249--1.051   0.069

Adjusted for age, sex, symptom onset time, Killip class, hypertension, diabetes, chronic kidney disease, cholesterol, LDL, hyperlipidemia, diseased vessels, number of stents, average stent diameter, prior MI, family history of CHD, family history of hypertension. NACE: Net adverse clinical event; *HR*: Hazard ratio; *CI*: Confidence interval; MI: Myocardial infarction; CHD: Coronary heart disease; LDL: Low-density lipoprotein-cholesterol.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

We retrospectively analyzed adult females and males with STEMI who underwent PCI. Females were found to have higher 30-day and long-term unadjusted outcomes. However, in a propensity-matched analysis, no differences were found between females and males for 30-day outcomes. There was, however, an apparent difference in long-term outcomes.

For the Chinese population, most studies aim to study the results of short-term follow-up of different gender.\[[@ref15][@ref16][@ref17]\] Our findings extend the previous literature on possible gender differences in short- and long-term outcomes in patients undergoing PCI in China. This population is large, and is a potentially different patient population from other countries, as China is preparing to embark on national efforts to improve the quality of AMI care.

Some differences between developed countries and China exist. Females in developed countries with STEMI undergoing PCI have a significantly increased risk for short-term NACE.\[[@ref18]\] In the present study of Chinese patients, the short-term risk was not found to be different. Based on the current data, and on our knowledge of gender differences in STEMI, there are several potential explanations for the difference of short-term risk in adult women compared with similarly aged men. Females with STEMI tended to be older, had more comorbidities including hypertension, diabetes, chronic kidney disease, and a higher Killip class, and more diseased vessels.\[[@ref19]\] Furthermore, sex differences in NACE became more pronounced by adjusted age and clinical characteristics,\[[@ref14]\] a finding that became attenuated and nearly disappeared. When the age of two groups of males and females is similar to the comorbidities, the effect of estrogen is highlighted. The main cause of this difference is the direct protective effect of hormone on the coronary artery and its impact on the risk factors of cardiovascular disease. Protections of estrogens on the coronary artery system include accelerating endothelial cell growth, inhibiting the migration and proliferation of smooth-muscle cells, and influencing the bioavailability of endothelial-derived nitric oxide.\[[@ref20]\] Other reasons for this international difference include different patient populations (≤60 years old) and type of AMI. This difference between previous studies and the current study requires further investigation.

For long-term NACE, females with STEMI after PCI had higher rates of NACE than males when developed countries were compared with China. After adjustment for confounders, gender was an important risk factor for STEMI with PCI and other secondary risk factors, such as hypertension and family history of CHD. There are several potential explanations for the higher risk for adverse outcomes in adult females compared with similarly aged males.

The reasons for the differences in NACE for female patients who showed poorer outcomes for STEMI following PCI are likely to be multifactorial and may include sex-specific biology, pathophysiology of myocardial infarction, psychosocial stressors, and potential intrinsic differences in angiogenesis. First, accompanying with the increase of aging, estrogen deficiency in adult women may be a potent risk factor for STEMI.\[[@ref21]\] Females were almost 5 years older than males in this study, and tended to have more hemodynamic impairment, which is in accordance with previous observations.\[[@ref22][@ref23][@ref24][@ref25]\] Second, 39.31% females had the history of smoking. Compared with males, smoking provides an increased risk for STEMI in females.\[[@ref26]\] Several studies have reported a particularly harmful effect of smoking on females, showing that the dose-dependent risk associated with smoking is significantly higher among females.\[[@ref14]\] Cigarette smoking induces oxidized stress and stimulates the release of vascular inflammatory cytokines, which result in endothelial dysfunction,\[[@ref15]\] and antagonizes the protective vasodilatory effects of estrogen in premenopausal females.\[[@ref27]\] Third, women ≤60 years of age had higher rates of any composite complications, such as hypertension than males in the study. Moreover, such risk factor was more strongly associated with the development of myocardial infarction in females than in males, as well as in younger females (≤60 years).\[[@ref28]\] What is more, uncontrolled blood pressure would be expected to increase vessel wall stress, a known stimulus to left ventricle remodeling, and result in interstitial fibrosis.\[[@ref29]\] The damage to target organ is more obvious over time, and these are the causes of poor prognosis in female AMI patients with hypertension. We also supposed that the relative risk conveyed by diabetes in females is greater than that in males. The incidence of coronary artery disease in patients with AMI is significantly higher than that in patients without diabetes. Meanwhile, diabetic patients have microvascular and myocardial damage caused by abnormal glucose metabolism. These are the causes of poor prognosis in diabetic female AMI patients.\[[@ref30]\] Fourth, females had significantly longer time from symptom onset to treatment. Apparently, females tended to postpone seeking medical care longer than males. We suppose that atypical symptoms are often a reason for patient\'s delay in seeking medical attention and should be incorporated in these education efforts. The symptom onset time of Chinese is longer than that of foreign standards time. In China, public recognition of the symptoms of common AMI should be raised, and the start of the catheter room as soon as possible can not only treat the delay but also reduce the patient\'s mortality. What is more, the incidence of plaque ruptures and subsequent thrombosis are more common in young male and older female patients with STEMI, while plaque erosion and microvascular embolization are more frequently reported in young female patients.\[[@ref31]\] It has been reported that erosive plaques have a higher level of critical stenosis as a result of greater maturation of thrombus material in comparison with ruptured plaques in pathology study.\[[@ref32]\] When plaque ruptures occur, thrombus formation is more frequently observed in females than males.\[[@ref33]\] Furthermore, in the current study, the number of stents were protective factors. Compared with females, the number of implanted stents was relatively much more in males, which might also account for the lower occurrence of 3-year NACE in males. At last, genes that might impact the effect of cardiovascular risk factors differentially by sex are still being investigated. For example, the Ser843 variant of glycoprotein IIb may be associated with an increased risk of MI in young women with other cardiovascular risk factors.\[[@ref34]\] These results suggest that family history of CHD is a risk factor for the poor prognosis of MI and more strict control of risk factors is needed for females, with estrogens decreasing, to reduce the incidence of STEMI.

In summary, higher mortality in females was mainly attributed to older age, worse risk-factor profiles, and greater comorbidities. After the propensity-matched adjustment in this study, the most of females with more risk factors were removed. By this way, female was still an independent predictor long-term NACE in STEMI patients undergoing PCI, suggesting that female was a special group. Therefore, for the management of STEMI, the 2012 European Society of Cardiology Guidelines consider female a special patient subset that requires specific awareness and attention during diagnosis and treatment.\[[@ref35]\] Particular attention should be given to females with STEMI so as to provide them with an equal quality of treatment as males. Thus, each sex should be considered with a distinct group of risk factors, undergoing temporal changes in an independent way. For this reason, reporting of future sex-specific results should be encouraged. Furthermore, baseline risks should be lowered with focused strategies for secondary prevention, particularly for females. It is vital that these comorbidities, including hypertension and diabetes mellitus, are actively improved in the general population to prevent the occurrence of cardiovascular disease in adults. To this end, a national prevention program for the management of cardiovascular diseases is urgently required because there is an absence of public preventive care programs or projects for coronary risk factors to reduce cardiovascular diseases in China.

There are some limitations to this study. First, as this was a clinical observational and a single-center study, it remains unclear why females had a greater prevalence of comorbidities than males. Second, this study was a retrospective analysis; the impact of the undervaluation of unmeasured factors on sex-related outcomes has not been addressed. Third, stent thrombosis was missing or lacking. Furthermore, other demographic factors, such as economic status, education background, and geographical region, were not considered. There were no data available regarding menopausal status and hormone replacement. Finally, the analysis was restricted to patients 60 years of age and who had STEMI, limiting the sample size and preventing definitive conclusions. Our observations should be regarded as hypothesis generating.

In conclusion, female gender was independently and significantly associated with increased 3-year NACE in this population of patients. Health-care providers should improve STEMI treatment at the national level by taking into consideration this specific at-risk group of females. Further studies are required to clarify the underlying mechanisms for this increased risk to develop improved therapeutic strategies for females with STEMI after PCI.
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